CL2024003237A1 - Métodos de administración de inhibidores de miosina - Google Patents

Métodos de administración de inhibidores de miosina

Info

Publication number
CL2024003237A1
CL2024003237A1 CL2024003237A CL2024003237A CL2024003237A1 CL 2024003237 A1 CL2024003237 A1 CL 2024003237A1 CL 2024003237 A CL2024003237 A CL 2024003237A CL 2024003237 A CL2024003237 A CL 2024003237A CL 2024003237 A1 CL2024003237 A1 CL 2024003237A1
Authority
CL
Chile
Prior art keywords
methods
administering
myosin
inhibitors
myosin inhibitors
Prior art date
Application number
CL2024003237A
Other languages
English (en)
Spanish (es)
Inventor
Sehnert Amy
V Perera Vidya
Merali Samira
Cheung Michael
Seto Dewey
Lockman Jeffrey
Papi Marie-Laure
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CL2024003237A1 publication Critical patent/CL2024003237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A61B8/065—Measuring blood flow to determine blood output from the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2024003237A 2022-04-26 2024-10-23 Métodos de administración de inhibidores de miosina CL2024003237A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335028P 2022-04-26 2022-04-26
US202263335209P 2022-04-26 2022-04-26
US202263336254P 2022-04-28 2022-04-28

Publications (1)

Publication Number Publication Date
CL2024003237A1 true CL2024003237A1 (es) 2025-02-07

Family

ID=86558746

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003237A CL2024003237A1 (es) 2022-04-26 2024-10-23 Métodos de administración de inhibidores de miosina

Country Status (12)

Country Link
US (4) US20230338378A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514355A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515491A (cg-RX-API-DMAC7.html)
KR (1) KR20250016125A (cg-RX-API-DMAC7.html)
CN (2) CN119789856A (cg-RX-API-DMAC7.html)
AU (1) AU2023260472A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249509A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003237A1 (cg-RX-API-DMAC7.html)
IL (1) IL316204A (cg-RX-API-DMAC7.html)
MX (1) MX2024013068A (cg-RX-API-DMAC7.html)
TW (1) TW202400570A (cg-RX-API-DMAC7.html)
WO (1) WO2023211872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585885B2 (en) * 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) * 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법

Also Published As

Publication number Publication date
US20240115568A1 (en) 2024-04-11
CA3249509A1 (en) 2023-11-02
IL316204A (en) 2024-12-01
JP2025515491A (ja) 2025-05-15
US20250360132A1 (en) 2025-11-27
CN119789856A (zh) 2025-04-08
KR20250016125A (ko) 2025-02-03
WO2023211872A1 (en) 2023-11-02
AU2023260472A1 (en) 2024-10-24
EP4514355A1 (en) 2025-03-05
CN120549937A (zh) 2025-08-29
MX2024013068A (es) 2025-02-10
US20230338378A1 (en) 2023-10-26
US20250288586A1 (en) 2025-09-18
TW202400570A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2024013068A (es) Métodos de administración de inhibidores de miosina
ZA202104678B (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
CL2023001351A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
NO20065676L (no) Forebyggelse av arteriell restenose med aktive vitamin D forbindelser.
CY1116925T1 (el) Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
CO2021015614A2 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
JOP20230090A1 (ar) نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
CL2025000195A1 (es) Métodos para el tratamiento de la miocardiopatía hipertrófica obstructiva.
MX2021009384A (es) Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
EP4208080A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPEUTIC TREATMENT OF PATIENTS WITH HEART FAILURE
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
EA202193276A1 (ru) Способы лечения холангиокарциномы
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
MX2025005021A (es) Inhibidores de cromanona alostericos de fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades